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Summary
Purpose: The presence of anti-ganglioside (GM1) or anti-glutamic acid decarboxylase
(GAD) antibodies has been reported in association with therapy-resistant epilepsy
mostly of focal origin. Our aim was to detect GM1 and GAD autoantibodies in patients
with juvenile myoclonic epilepsy (JME) and to evaluate their association with rarely
encountered therapy-resistant cases in this idiopathic generalised epilepsy syndrome.
Methods: Ninety-six consecutive JME patients and 25 healthy normal control subjects
were included to the study. We investigated anti-GM1 and anti-GAD antibodies
with enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay (RIA),
respectively.
Results: We found anti-GM1 antibodies in one of 96 (1.04%) JME patients and in one
out of 25 (4%) healthy controls, without reaching a significant difference between the
titres. Anti-GAD antibodies were detected in 5.8% of the patients and in 4% of the
healthy controls. Both antibodies did not have any association with therapy-resistant
cases and with any other relevant parameters.
Conclusions: The results of our pilot study suggested that anti-GM1 and anti-GAD
antibodies are rare and they did not associate with therapy-resistance and other
parameters in JME syndrome.
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As a well-characterised idiopathic generalised epi-
leptic syndrome, juvenile myoclonic epilepsy (JME)
shows marked genetic and clinical heterogeneity.
Different loci at chromosomes 6p, located in vicinity
of the HLA region as well as at 15q have been
implicated in the expression of JME.1,2 Most of the
patients may become seizure-free with valproateby Elsevier Ltd. All rights reserved.
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patients (15.5%) whose seizures do not respond to
VPA.3 Distinctive features are not clearly identified
for this small refractory subgroup of JME.
The presence of autoantibodies against ganglio-
side (GM1), a ganglioside with monosialo group was
reported in patientswith refractory partial epilepsy.4
On the other hand, two case—control studies5,6
demonstrated anti-glutamic acid decarboxylase
(GAD) antibody positivity in uncontrolled epilepsy,
apart from anecdotal case reports related on the
same interesting association, which could be rather
coincidental in patients with Stiff Man’s syndrome.7—
10 Although, this association was noted almost only
for focal epilepsies, the highest concentration of
anti-GAD antibody was found in a patient with JME
out of the studied common epilepsy types and aetiol-
ogies of both idiopathic and symptomatic nature.5
This finding, taken together with limited data about
the mechanism of therapy-resistant course in some
cases with JME, inspired us to explore the hypothesis
that these autoantibodies might be associated with
therapy resistance in JME.
Therefore, we designed a cross-sectional study to
find the prevalence of anti-GM1 and anti-GAD auto-
antibodies and to evaluate their associations with
rare, drug-resistant cases of JME syndrome.Methods
Clinical analysis and serum samples
We investigated the sera from 96 consecutive JME
patients and 25 age-matched normal healthy con-
trols. The control subjects were all examined clini-
cally to exclude any other neurological and systemic
disease.
All patients and control subjects were included
after obtaining their written informed consent.
None of the patients had a history of any other
neurological disease, insulin dependent diabetes
mellitus (IDDM), stiff person syndrome (SPS) or an
autoimmune disease. Serum samples were collected
at the time of admission of the patients and stored
at 70 8C until assayed.
JME patients were diagnosed according to the
criteria of the International League Against Epi-
lepsy.11 We defined the therapy-resistant course
for JME syndrome as one or more generalized
tonic—clonic seizures per year in the last 2 years
or two or more myoclonic seizures per month
despite adequate monotherapy with therapeutic
serum levels.
All available clinical and EEG features were inves-
tigated for any correlation with the antibodyresponses. Possible effects of current received
anti-epileptic drugs (AED) on the antibody concen-
trations were also investigated.
Anti-GM1 antibody assay
The presence of serum antibodies against GM1 gang-
liosides in IgG and IgM isotypes were determined
with a standard enzyme-linked immunosorbent
assay (ELISA). All serum samples were assayed in
triplicate on flat-bottom wells of 96-well microtitre
plates (Polysorp, Nunc, Denmark). ELISA was per-
formed, briefly, by coating plate wells with or with-
out 200 ng of GM1 (Sigma Chemicals, Poole, UK) in
20 ml methanol per well and evaporating to dryness.
Non-specific binding sites were saturated with
150 ml 3% bovine serum albumin (BSA) in phos-
phate-buffered saline (PBS) for 1 h at room tem-
perature. Then 100 ml of control and patients’
serum samples, diluted as 1/100 in 3% BSA were
added and incubated overnight at 4 8C. After four
washes with 250 ml of 0.3% BSA in PBS, 100 ml horse-
radish peroxidase-conjugated goat anti-human IgG
or IgM diluted as 1/1000 were added and the plates
were incubated 1.5 h at room temperature (Sigma
Chemicals, Poole, UK). The wells were washed as
before, followed by the addition of 100 ml O-phe-
nylendiamine dihydrochloride (OPD). After 45 min
incubation, the reaction was stopped with 100 ml
4 M H2SO4 solution. Optical densities (OD) were read
at 450 nm with a microplate reader. We calculated
‘‘corrected OD’’ values by subtracting the blank well
OD from the coated well OD for each sample.
Samples were considered as ‘‘positive’’ if their
corrected OD was above 2 standard deviations
(S.D.s) of the mean of 25 normal controls’measure-
ments. Positive samples titrated by serial dilution
above 1/100. The titre for each sample was assigned
as the highest dilution in which the absorbance was
0.1 units greater than in the corresponding negative
well.
Anti-GAD antibody assay
Anti-GAD antibodies were measured in the serum of
10 ‘‘therapy resistant’’ and randomly selected 59
JME patients as well as in same 25 normal controls.
Anti-GAD antibodies were investigated by a radio-
immunoassay (RIA) according to the manufacturer’s
instructions (GAD–—Antibody Assay, Diagnostika
GmBH, Germany). The positivity cut-off was set
at 2 S.D. above the mean of 25 normal controls’
measurements. All samples were tested in duplicate
and the mean values were taken for presentation.
Random blood glucose levels were measured in
all patients and controls to screen for undiagnosed
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Table 2 Median values of corrected OD for anti-GM1
antibodies of IgM isotype and anti-GAD antibodies’
concentrations in JME, in normal controls and in sub-
groups according to response to treatment.
GM1
median
GAD
median
(U/ml)
JME 0.15 0.73
Normal control 0.14 0.73
‘‘Therapy resistant’’ JME 0.19 0.56
‘‘Benign’’ JME 0.15 0.75
GAD: glutamic acid decarboxylase; GM1: ganglioside; JME:
juvenile myoclonic epilepsy; and OD: value of optical density.IDDM. The sera of patients with elevated GAD auto-
antibody concentrations were tested for other auto-
antibodies, including pancreatic islet cell and anti-
nuclear antibody, anti-nuclear cytoplasmic antibody
(ANCA), anti-cardiolipins, lupus anti-coagulant,
anti-dsDNA, thyroid microsomal and peroxisomal
antibodies, anti-thyroglobulin, anti-gliadin and
anti-intrinsic factor antibodies and rheumatoid
factor.
Statistical analysis
Statistical calculations were performed with SPSS
10.0 software. Mann—Whitney U (MWU) test was
applied to calculate the significance of differences
between JME and normal controls. One-way analysis
of variance (ANOVA) test was used to demonstrate
any association of the AEDs with anti-GAD as well as
anti-GM1 levels. Finally, linear regression test was
used to compare the anti-GAD concentration versus
anti-GM1 reactivity.Results
Ninety-six consecutive JME patients followed for
more than two years (mean follow-up period was
11.4  7.2 years) and 25 age-matched normal
healthy control subjects were enrolled in this study.
Descriptive findings of all subjects were summarized
in Table 1.
For GM1 antibody, median ‘‘corrected OD’’ values
of JME patients and normal controls were shown in
Table 2. We found that anti-GM1 antibodies of IgM
isotype were positive in only 1 (1.04%) out of 96 JME
patients and 1 out of 25 (4%) normal controls. The
detected titres were 1/1600 in the JME patient and
1/800 in the control subjects. For IgG isotype, no
positivity was detected in the patients as well as in
normal controls (data not shown).Table 1 Descriptive findings of the study subjects.
JME group Normal
controls
N (number of cases) 96 25
Age (years, mean  S.D.) 25.1  7.0 24.6  3.8
M/F 40/56 9/16
Duration of epilepsy
(years, mean  S.D.)
10.9  7 —
Presence of febrile
convulsion (%)
18 (18.7) 1 (4)
Family history of
epilepsy (%)
31 (32.3) —
JME: juvenile myoclonic epilepsy; S.D.: standard deviations.Anti-GAD antibody concentrations were also low
in both groups without a significant difference
(Table 2). However, four patients had antibodies
above cut-off value (5.8%), when the positivity was
set at 2 S.D. above the mean of 25 normal controls’
measurements. These 4 patients have the highest
anti-GAD antibody levels (3.26, 2.05, 2.03, 1.58 U/
ml, respectively) and all had photosensitivity,
except for one of them, as a common EEG charac-
teristic. However, the JME patients with photosen-
sitivity as a whole did not show any statistical
difference in anti-GAD concentrations when com-
pared with the main group. These four patients did
not show any other difference from the main JME
group with regard to the clinical features and they
had benign course with VPA therapy. None of them
had a family history of IDDM or any autoimmune
disease. They were also tested for other given
autoantibodies, all with negative results. The nor-
mal subject with a positivity against GAD antibodies
has a concentration of 1.51 U/ml and we have
learnt that this female subject was pregnant at
the time of blood draw and did not know her con-
dition.
We found only 10 patients with therapy-resistant
course for JME syndrome according to our criteria.
No significant differences could be demonstrated
between these ‘‘therapy resistant’’ and ‘‘benign’’
groups of JME patients when tested for either anti-
GM1 or anti-GAD autoantibodies. The anti-GAD con-
centrations did not correlate with GM1 antibodies.
Sixty-nine JME patients were under VPA mono-
therapy (group 1), and six patients were taking
politherapy with two or more drug combinations
such as VPA, phenobarbital, lamotrigine (group 2).
The remaining 19 patients were taking either clo-
nazepam or phenobarbital monotherapy (group 3).
Two JME patients were not under anti-epileptic
treatment. The subgroups according to various
anti-epileptic drug treatments did not show any
correlation with either GM1 or GAD antibody levels.
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The role of anti-GM1 antibodies in the pathogenesis
of epilepsy has been investigated mainly in experi-
mental models.12 Epileptogenic action of these anti-
bodies directed against GM1 gangliosides was
demonstrated in rats.13 Such antibodies have been
reported to increase release of GABA after depolar-
isation, possibly exerting a convulsant effect by
interfering with kindling or inhibiting the interac-
tion of GABA with synaptic receptors and/or trans-
port sites.14
In a recent clinical study, anti-GM1 antibodies
were detected in four out of 64 patients with partial
epilepsy.4 A further case with refractory partial
epilepsy was reported associating with anti-GM1
antibodies.15 Our hypothesis was to test the pre-
sence of GM1 autoantibodies in therapy-resistant
cases in JME, which was a generalised epileptic
syndrome, being an entirely new target for screen-
ing. However, the titres of anti-GM1 autoantibodies
were found very low in JME patients and not differ-
ent from normal healthy controls.
GAD is localized largely to neurons and in parti-
cular to those that appear to use GABA as a neuro-
transmitter.16 Recently, a mutation of GABRA1 gene
(the gene encoding the alfa 1 subunit of GABA
receptor) was demonstrated in an autosomal domi-
nant form of JME.17 Peltola et al.6 studied the
prevalence of anti-GAD antibodies in a substantial
group of patients with therapy-resistant partial epi-
lepsy and generalized epilepsy, and anti-GAD anti-
bodies were found only in eight patients with partial
epilepsy. We found low concentrations of anti-GAD
autoantibodies in JME patients, which were not
different from normal controls.
We could not demonstrate any relationship
between GAD autoantibody titers and ‘‘therapy-
resistant’’ course in JME in our study. Rantala
et al.18 measured GAD antibodies in an unselected
population of 114 children with different types of
epilepsy, and none of the children were positive for
GAD antibodies. Therefore, they concluded GAD
antibody testing cannot be recommended in unse-
lected cases of childhood epilepsy. Our results in
JME syndrome support their conclusion.
Immune responses in patients with epilepsy may
present a genetic coupling to epilepsy phenotype or
may occur as consequence of long-term anti-epilep-
tic treatment. VPA, the drug of choice for JME,
may cause immunological problems like develop-
ment of drug-induced systemic lupus erythematosus
(SLE)19—21 and lupus anti-coagulant.22 We could not
demonstrate any association of the AEDs with
anti-GAD as well as anti-GM1 positivity in our pilot
study.The limitation of our study was the known imbal-
ance between the ‘‘therapy resistant’’ and
‘‘benign’’ groups in JME (only 10% was defined as
therapy resistant) related to our cross-sectional
study design. Another weakness was the limited size
of normal control subjects for defining the normal
population levels of the investigated antibodies.
Both of these points have obviously reduced the
statistical power to draw definite conclusions.
Nevertheless, we believe that low levels of both
GM1 and GAD autoantibodies found in our study may
point out that these antibodies do not play a marked
role for therapy-resistance in this idiopathic gener-
alised epileptic syndrome.Acknowledgments
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